MetaCap

Ginkgo Bioworks (DNA) vs REGENXBIO (RGNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ginkgo Bioworks (DNA) has outperformed REGENXBIO (RGNX) over the past year, losing 8.7% versus a loss of 39.3%. Over five years, RGNX leads with a -76.9% price change compared with -98.5% for DNA. Ginkgo Bioworks is the larger company by market cap ($483.5 million vs $473.4 million), about 1.0 times the size, while REGENXBIO is growing revenue faster (+104.5% vs -25.1%).

REGENXBIO converts more of its revenue into profit, with a net margin of -113.8% versus -183.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DNA-8.69%RGNX-39.32%
+90%+16%-59%
Nov 21, 20251 yearNov 20, 2026
DNA-98.61%RGNX-78.63%
+10%-47%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DNA versus RGNX key metrics
MetricDNARGNX
Share price$7.46$7.16
Market cap$483.54M$473.44M
1-day change-9.02%-0.28%
YTD return-10.23%-50.28%
1-year return-8.69%-39.32%
5-year return-98.45%-76.87%
EPS (TTM)$-4.24$-3.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$170.16M$170.44M
Revenue growth (YoY)-25.06%+104.54%
Net income (latest FY)$-312.76M$-193.88M
Operating margin-185.29%-94.58%
Net margin-183.81%-113.75%
52-week high$18.22$16.19
52-week low$5.37$5.46
Distance from 52-week high-59.06%-55.78%
Analyst consensusunderperformstrong_buy
Avg. price target upside+7.24%+198.88%
Average volume2.53M1.39M
Shares outstanding53.94M66.12M
Employees485371
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DNA has outperformed RGNX by 30.6 percentage points over the past year.
  • REGENXBIO is more profitable, keeping -113.8 cents of every revenue dollar as net income versus -183.8 cents for Ginkgo Bioworks.
  • REGENXBIO grew revenue faster in its latest fiscal year (+104.54% vs -25.06%).

About Ginkgo Bioworks

DNA stock →

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees

About REGENXBIO

RGNX stock →

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees

DNA vs RGNX FAQ

Which is bigger, Ginkgo Bioworks or REGENXBIO?

Ginkgo Bioworks (DNA) is larger, with a market capitalization of $483.54M compared with $473.44M for REGENXBIO (RGNX).

Which stock has performed better over the past year, DNA or RGNX?

DNA returned -8.69% over the past 12 months, compared with -39.32% for RGNX (price return, excluding dividends). Past performance does not predict future results.

Are Ginkgo Bioworks and REGENXBIO in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons